CIAM
RCUS icon

Caitong International Asset Management’s Arcus Biosciences RCUS Stock Holding History

Caitong International Asset Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$617 Sell
20
-1,382
-99% -$34.2K ﹤0.01% 1673
2026
Q1 		$30.3K Buy
1,402
+1,047
+295% +$22.6K 0.01% 921
2025
Q4 		$8.46K Buy
+355
New +$7.24K ﹤0.01% 1169
2025
Q3 		– Sell
-417
Closed -$3.39K – 2412
2025
Q2 		$3.39K Buy
+417
New +$3.56K ﹤0.01% 1183

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Caitong International Asset Management's RCUS Position: Q2 2026 in Review

Caitong International Asset Management reduced its Arcus Biosciences (RCUS) stake by 99% in Q2 2026, selling an estimated $34.2K and leaving 20 shares worth $617. The position accounts for ﹤0.01% of the portfolio, ranked #1673.

Caitong International Asset Management first reported a position in RCUS in Q2 2025 and has held it in 4 quarters since. The position peaked at $30.3K in Q1 2026. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Caitong International Asset Management held 20 shares of Arcus Biosciences worth $617 as of Q2 2026.
  • Caitong International Asset Management sold 1,382 Arcus Biosciences shares in Q2 2026, an estimated $34.2K.
  • Arcus Biosciences made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1673 holding.
  • Caitong International Asset Management first reported a position in Arcus Biosciences in Q2 2025 and has held it in 4 quarters since.
  • Caitong International Asset Management's Arcus Biosciences position peaked at $30.3K in Q1 2026.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.